Celecoxib vs Etodolac — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Nonsteroidal Anti-inflammatory Drug

Celecoxib

Brand: CELEBREX

First FDA approval: 1998-10-02

Nonsteroidal Anti-inflammatory Drug

Etodolac

First FDA approval: 1998-03-11

Lowest NADACAcquisition cost floor across all NDCs

$0.071Per unit

$0.253Per unit

Average NADACAcross all dosage forms and strengths

$1.04Up to $30.65

$0.660Up to $1.07

Generic manufacturersActive ANDA holders — FDA Orange Book

1867 total ANDAs filed

1134 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$257.9MFull year

$15.9MFull year

Part D claims (CY24)Total fills, all strengths

8.8M3.3M beneficiaries

391K170K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$29Per claim, all NDCs

$41Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1Minimal friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

16Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes18 manufacturers

Yes11 manufacturers